18593-51-6

Basic information

• Product Name: 6-ethylthieno[2,3-d]pyrimidin-4(3H)-one
• Synonyms: 6-ethylthieno[2,3-d]pyrimidin-4(3H)-one;6-Ethyl-3H-thieno[2,3-d]pyriMidin-4-one;6-ethyl-3H-thieno[3,2-e]pyrimidin-4-one;A1760/0074713;AG-205/12040018;BAS 00821708;ChemDiv2_002305;IDI1_012791
• CAS NO: 18593-51-6
• Molecular Formula: C₈H₈N₂OS
• Molecular Weight: 180
• Mol File: 18593-51-6.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 6-ethylthieno[2,3-d]pyrimidin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-ethylthieno[2,3-d]pyrimidin-4(3H)-one(18593-51-6)
• EPA Substance Registry System: 6-ethylthieno[2,3-d]pyrimidin-4(3H)-one(18593-51-6)

Safety Data

• Statements: 20/21/22
• Safety Statements: 3/9-36/37
• Hazardous Substances Data: 18593-51-6(Hazardous Substances Data)

Usage

Chemical Properties

White solid

Upstream product

• 4507-13-5 ethyl 2-amino-5-ethylthiophene-3-carboxylate 
• 77287-34-4 formamide 
• 19156-63-9 2-amino-5-ethylthiophene-3-carboxylic acid methyl ester 

Downstream Products

• 81136-42-7 4-chloro-6-ethylthieno<2,3-d>pyrimidine 
• 313534-29-1 N-(6-ethylthieno[2,3-d]pyrimidin-4-yl)glycine 

Relevant articles and documents

Structure-guided discovery of a selective mcl-1 inhibitor with cellular activity

Myeloid cell leukemia 1 (Mcl-1), an antiapoptotic member of the Bcl-2 family of proteins, whose upregulation when observed in human cancers is associated with high tumor grade, poor survival, and resistance to chemotherapy, has emerged as an attractive target for cancer therapy. Here, we report the discovery of selective small molecule inhibitors of Mcl-1 that inhibit cellular activity. Fragment screening identified thienopyrimidine amino acids as promising but nonselective hits that were optimized using nuclear magnetic resonance and X-ray-derived structural information. The introduction of hindered rotation along a biaryl axis has conferred high selectivity to the compounds, and cellular activity was brought on scale by offsetting the negative charge of the anchoring carboxylate group. The obtained compounds described here exhibit nanomolar binding affinity and mechanism-based cellular efficacy, caspase induction, and growth inhibition. These early research efforts illustrate drug discovery optimization from thienopyrimidine hits to a lead compound, the chemical series leading to the identification of our more advanced compounds S63845 and S64315.

NEW AMINOACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I): wherein R1, R2, R5, R6, R7, R12, X, Y, A, E and n are as defined in the description. Medicaments.

IRAK INHIBITORS AND USES THEREOF

The present invention relates to compounds and methods useful for inhibiting one or more interleukin-l receptor-associated kinases ("IRAK"). In some embodiments, a provided compound inhibits IRAK-1 and IRAK-4. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.